Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc.
WKN: A1XCY0 / Symbol: RARE / Name: Ultragenyx / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
?
-0,65 %
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Piper Sandler from $135.00 to $140.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $118.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $95.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $118.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Piper Sandler from $140.00 to $115.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at JPMorgan Chase & Co. from $104.00 to $117.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at Morgan Stanley from $64.00 to $65.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at William Blair. They set an "outperform" rating and a $65.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $64.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Wells Fargo & Company from $88.00 to $65.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Morgan Stanley from $65.00 to $55.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Cantor Fitzgerald from $112.00 to $105.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $105.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $65.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Truist Financial Corporation from $100.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at TD Cowen from $86.00 to $75.00. They now have a "buy" rating on the stock.
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Barclays PLC from $81.00 to $50.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
Neueste Beiträge
Morgan_Stanley in Rio Tinto plc ADR diskutieren